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Introduction: Huntington’s disease (HD) is an autosomal dominant disorder caused by an expanded CAG repeat
on the short arm of chromosome 4 resulting in cognitive decline, motor dysfunction, and death, typically occurring
15 to 20 years after the onset of motor symptoms. Neuropathologically, HD is characterized by a specific loss of
medium spiny neurons in the caudate and the putamen, as well as subsequent neuronal loss in the cerebral cortex.
The transgenic R6/2 mouse model of HD carries the N-terminal fragment of the human HD gene (145 to 155 repeats)
and rapidly develops some of the behavioral characteristics that are analogous to the human form of the disease.
Mesenchymal stem cells (MSCs) have shown the ability to slow the onset of behavioral and neuropathological deficits
following intrastriatal transplantation in rodent models of HD. Use of MSCs derived from umbilical cord (UC) offers an
attractive strategy for transplantation as these cells are isolated from a noncontroversial and inexhaustible source and
can be harvested at a low cost. Because UC MSCs represent an intermediate link between adult and embryonic tissue,
they may hold more pluripotent properties than adult stem cells derived from other sources.
Methods: Mesenchymal stem cells, isolated from the UC of day 15 gestation pups, were transplanted intrastriatally into
5-week-old R6/2 mice at either a low-passage (3 to 8) or high-passage (40 to 50). Mice were tested behaviorally for 6 weeks
using the rotarod task, the Morris water maze, and the limb-clasping response. Following behavioral testing, tissue sections
were analyzed for UC MSC survival, the immune response to the transplanted cells, and neuropathological changes.
Results: Following transplantation of UC MSCs, R6/2 mice did not display a reduction in motor deficits but there
appeared to be transient sparing in a spatial memory task when compared to untreated R6/2 mice. However, R6/2
mice receiving either low- or high-passage UC MSCs displayed significantly less neuropathological deficits, relative to
untreated R6/2 mice.
Conclusions: The results from this study demonstrate that UC MSCs hold promise for reducing the neuropathological
deficits observed in the R6/2 rodent model of HD.Introduction
Huntington’s disease (HD) is an autosomal dominant
disorder caused by an expanded and unstable CAG trinu-
cleotide repeat that causes a progressive degeneration of
neurons, primarily in the putamen, caudate nucleus and
cerebral cortex. The underlying pathology of HD is initiated* Correspondence: dunba1g@cmich.edu
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reproduction in any medium, provided the orwhen the gene that codes for the huntingtin (HTT) protein,
located on the short arm of chromosome 4, contains an
increased number of CAG repeats [1]. Adult onset HD
is characterized by cognitive impairment and psychiatric
disturbances, such as irritability, aggressiveness and
depression, which precede involuntary motor disturbances
[1,2], with death occurring 15 to 20 years later.
The R6/2 mouse model of HD expresses the N-terminal
portion of human htt, containing a highly expanded CAG
repeat (145 to 155), and develops progressive neurological
phenotypes resembling HD [3]. At birth R6/2, mice are
indistinguishable from wild-type littermates and have a. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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they begin to express the HD phenotype, which consists
of neurological signs of stereotypical hindlimb grooming,
dyskinesia, irregular gait and motor dysfunction [3,4].
Mesenchymal stem cells (MSC) are multipotent cells
derived from adult tissue that are readily available and
easily accessed. Previous studies have shown that MSCs
can suppress the immune response following transplant-
ation and provide functional efficacy in rodent models of
HD. As such, MSCs hold considerable promise as a source
for an effective cell therapy [5-7]. However, as MSCs can
be obtained from multiple sources, finding the ideal cell
source is currently of great interest for optimizing efficacy
of stem cell therapies.
As observed previously [8], transplanted bone-marrow-
derived MSCs, while capable of reducing behavioral and
histological deficits in the R6/2 mouse, did not generate
new neurons following transplantation in the mouse striata.
Due to this issue, stem cells from other sources, specifically
from birth-associated tissues, are gaining interest [5].
The umbilical-cord (UC) is an attractive source of MSCs,
as they represent an intermediate link between adult and
embryonic tissue, and can be isolated from a noncontro-
versial source and can be harvested at a low cost [9,10].
Human UC MSCs have also been shown to have a higher
harvest rate when compared to bone-marrow-derived
cells, making it possible to isolate a substantial number of
cells, while limiting the time and number of passages in
culture to produce clinically-relevant numbers of cells for
transplantation [11,12].
UC stem cells hold advantages over other types of
adult stem cells, as it has been shown that UCs do not
require human leukocyte antigen (HLA) matching [13,14].
Further, cord-blood is easily cryopreserved, allowing for
bio-banking and expansion for future use [10]. It has also
been reported that UC MSCs express the pluripotent
markers Oct-4, Nanog and Sox-2, albeit at much lower
levels than embryonic cells [15]. The expression of pluri-
potent markers may be due to the nature of the umbilical
cord, which lies at an intermediate position between
the embryo and the adult organism during development
(although the migration of fetal cells between the embryo
and adult is not fully understood [16]. It is speculated that
some of the fetal cells get ‘trapped’ in the Wharton’s jelly
of the umbilical cord [16].
With this potential for pluripotency, many researchers
have explored the use of UC MSCs as a cell replacement
therapy in neurodegenerative disorders. Several groups
have reported that human UC MSCs express neuronal
precursor markers and can differentiate into mature neu-
rons in vitro, when exposed to the differentiation signals
[10,17-21]. In the brain of a Parkinsonian rat, transplanted
UC MSCs survived, proliferated and expressed phenotyp-
ical markers of dopaminergic neurons [22]. Several studieshave also reported behavioral improvements following
human UC MSCs transplantations in experimental rat
models of middle cerebral artery occlusion [23-25].
The current study tested the efficacy of UC MSCs in
the R6/2 mouse model of HD. It was hypothesized that
MSCs isolated from the UC would possess the ability to
differentiate into neuronal lineages in vivo following
intra-striatal transplantation. UC MSCs may offer an ex-
citing avenue for transplantation therapies if they are able
to exert beneficial factors similar to bone-marrow MSCs,
while possessing the ability to differentiate into neuronal
lineages.
In order to expand stem cells, specifically MSCs, in
sufficient numbers for transplantation, in vitro passaging
is required, and passaging cells has been shown to alter
the properties of these cells [26]. Our previous work
suggested that reducing the number of cell passages may
increase transplant survivability in rat bone-marrow MSCs
and increase their efficacy in reducing behavioral deficits
in the 3-nitropropionic acid rat model of HD [27].
The goals of the present experiment were to test: (1) the
efficacy of UC MSCs in the R6/2 transgenic mouse model
of HD; and (2) how passaging of MSCs in vitro alters the
functional outcome following transplantation. Behavioral
and histological analyses were performed to examine the ef-
ficacy of both low-passage (P3 to 8) and high-passage (P40
to 50) UC MSCs transplanted into the striata of R6/2 mice.
Methods
In vitro cell characterization
The extraction of UC MSCs was performed from day 15
gestation pups of wild-type (WT; C57/BL6 background;
Jackson Laboratory, Bay Harbor, ME, USA). Briefly, the
placenta was discarded from the distal end of the umbil-
ical cord and the fetus and held above a sterile Petri dish
with sterilized forceps. The cells were then pushed out
of the umbilical cord using a separate set of sterile for-
ceps. The UC was then diluted in 10 mL MSC medium
(Alpha Modified Eagles Medium (αMEM: Invitrogen,
Carlsbad, CA, USA) with 10% fetal bovine serum (FBS;
Invitrogen), 10% horse serum (HS; Invitrogen), and
5 mg/mL streptomycin and 5 UI/mL penicillin (Sigma;
St. Louis, MO)) and collected in a 15 mL Falcon tube
and centrifuged at 1,500 rpm for seven minutes at 4°C.
The cells were then counted and plated in a 75 cm2 flask
containing 15 mL of MSC medium.
Following incubation for 48 hours at 37°C, 5% CO2,
UC MSCs were allowed to attach and non-adherent cells
or debris was removed and replaced with fresh MSC
medium. When the UC MSCs reached 85% confluency,
the cells were passaged. Briefly, the culture medium was
aspirated, 0.25% trypsin-ethylenediaminetetraacetic acid
(EDTA) solution (Sigma) was added for five minutes
to detach the cells, then the trypsin was deactivated
Table 1 Primer sequences used in quantitative RT-PCR
analysis
Primer Sequence
GAPDH Forward AAG AGA GGC CCT ATC CCA A
GAPDH Reverse CAG CGA ACT TTA TTG ATG GTA
BDNF Forward GAA GAG CTG CTG GAT GAG GAC
BDNF Reverse TTC AGT TGG CCT TTT GAT ACC
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containing the cells was collected and centrifuged at
1,500 rpm for seven minutes at 4°C. The supernatant was
removed and the pellet was then re-suspended, counted
and replated at a density of 8,000 cells/cm2 in a new 75 cm2
flask (Phenix; Candler, NC) with fresh MSC media.
The low-passage and the high-passage MSCs were ana-
lyzed by immunocytochemistry (ICC) and by flow cytome-
try. Briefly, for ICC, UC MSCs were plated into six-well
plates containing poly-L-ornithine coated glass coverslips
(25 mm #1; Fisher Scientific; Waltham, MA) and cultured
in MSC medium. At 80% confluency, the cells were fixed
with 4% paraformaldehyde in 0.1 M PBS at 4°C for ten mi-
nutes. To block non-specific binding sites, the coverslips
were incubated for one hour at room temperature with
10% normal goat serum (Sigma). Following blocking, the
coverslips were incubated in primary antibodies overnight
at 4°C. Primary antibodies included CD45 (1/500; Abcam;
Cambridge, MA) and SCA-1 (1/500; Abcam). After
24 hours, the coverslips were then rinsed and incubated for
one hour at room temperature with the appropriately
conjugated secondary antibodies. The secondary anti-
bodies included AlexaFluor488 and AlexaFluor594 (1/300;
Invitrogen). The coverslips were then rinsed and incubated
in Hoechst 33358 (1/1000; Thermo Scientific; Waltham,
MA) for five minutes at room temperature to visualize cell
DNA and then mounted onto glass slides using Fluoro-
mount (Sigma). Slides were imaged at 20x using a Zeiss
Axiovert 200 M inverted fluorescent microscope.
Flow cytometry analysis followed previously published
protocols [28]. Briefly, 200,000 to 300,000 cells were
plated into each well of a round-bottom 96-well plate
following a passage. The cells were rinsed in 0.1 M PBS
containing 1% BSA (Sigma) and 0.1% azide (Sigma) and
centrifuged at 2,500 rpm for one minute at 4°C. The cells
were then resuspended in 30 μL of primary antibodies for
one hour at 4°C. The primary antibodies and dilutions are
described above for ICC with the addition of stage specific
embryonic antigen 4 (SSEA4, a marker of stem cells, 1/500;
Abcam), major histological complex class I (MHC Class
I, a receptor for T cell identification; 1/500; Abcam) and
MHC Class II, a marker of antigen-presenting cells and
lymphocytes. The cells were then rinsed twice and incu-
bated in secondary AlexaFluor488 (1/300; Invitrogen)
for one hour at 4°C. The cells were again rinsed twice
and fixed using 4% paraformaldehyde for ten minutes on
ice. The cells were rinsed and stored at 4°C until analysis
was performed using a LSR II (BD Bioscience, San Jose,
CA, USA).
RNA isolation was performed from UC MSC cell cultures
using a Qiagen RNeasy system (Germantown, MD, USA).
All procedures followed the manufacturer’s guidelines.
Briefly, two million cells were isolated following passaging
and stored at −80°C in 200 μLTrizol (Sigma). Then, 300 μLof buffer RLT was added to the cell pellet and transferred
into a gDNA Eliminator tube and centrifuged at 8,000 × g
for one minute, at which point 350 μL of 70% ethanol
was added to the flow-through and mixed thoroughly.
All contents of the flow-through were then added to an
RNeasy spin column and centrifuged at 8,000 × g for
30 seconds. The flow-through was discarded, 700 μL of
RW1 buffer was added to the RNeasy spin column, and
the column was centrifuged at 8,000 × g for 30 seconds.
The flow-through was again discarded, and 500 μL of
RPE buffer was added to the RNeasy spin column and
the column was centrifuged at 8,000 × g for 30 seconds.
The RNeasy spin column was placed in a new collection
tube, 30 μL of RNase-free water was added to the spin
column, and the column was centrifuged at 8,000 × g
for one minute. Purified RNA, in the collection tube,
was analyzed using a NanoDrop2000 spectrophotometer
(ThermoScientific, Asheville, NC, USA) and was stored
at −20°C until used for cDNA synthesis. A QuantiTect
Reverse Transcription Kit (Qiagen) was used for cDNA
synthesis following the manufacturer’s guidelines. Briefly,
RNA was incubated at 42°C for two minutes in a genomic
DNA elimination buffer. The solution was transferred to a
reverse-transcription master mix and incubated at 42°C
for 30 minutes and then at 95°C for three minutes to
inactivate the reverse transcriptase. The cDNA was
stored at −20°C until used in quantitative PCR experiments.
Primer used for quantitative PCR was brain-derived
neurotrophic factor (BDNF). All values were normalized
to the housekeeping gene GAPDH and to a reference
sample of tail-tip fibroblasts. Sequences are shown in
Table 1.
Animals
All procedures were carried out under the approval
of Central Michigan University Animal Care and Use
Committee. Male and female R6/2 and WT mice, were
housed at 22°C under a 12 hour light/12 hour dark reverse
light cycle (lights on at 0900) with ad libitum access to
food and water. The mice were randomly assigned to one
of the following four groups, with the exception of having
the groups balanced by gender and genotype: (1) sham-
operated (Hanks Balanced Salt Solution; HBSS; Gibco;
Grand Island, NY, injection into the striatum) WT mice
(WT; n = 17); (2) sham-operated R6/2 (R6/2; n = 12) mice;
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(R6/2 UC Low; n = 9); and (4) R6/2 mice transplanted with
high-passage UC MSCs (R6/2 UC High; n = 8).
UC MSC transplantation
At five weeks of age, mice were anesthetized with iso-
flurane gas and O2. The heads of the mice were shaved
and cleaned using chlorehexadine (Molnlycke Healthcare,
Brunswick, ME, USA). Lidocaine gel (2%, Hi-Tech Phar-
macal, Co Inc, Amityville, NY, USA) was placed on the tip
of the ear bars prior to placing the mouse in the stereotaxic
apparatus. The mice were then placed in the stereotaxic
device and the anesthesia was maintained with isoflurane
gas and O2 for the duration of the surgery. A midline
incision was made on the scalp and the skin was
retracted, exposing bregma. Two burr holes (0.5 mm)
were placed directly over the neostriatum (coordinates
relative to bregma: anterior +0.5 mm; lateral + 1.75 mm
and −1.75 mm; tooth bar set at −3.3 mm). Prior to trans-
plantation, MSCs at either low passage (P3 to 8) or high
passage (P40 to 50) were pre-labeled with Hoechst 33358
(5 μg/mL, Sigma) and resuspended at a density of 200,000
cells per microliter in HBSS. The cells were loaded into a
10 μL Hamilton microsyringe and bilaterally transplanted
(−2.5 mm ventral to dura) at a constant rate of 0.33 μL/
minute for three minutes. Following the first injection, the
syringe was left in place for three minutes, raised 1 mm,
and injected a second time, for a total injection volume
of 2 μL containing approximately 400,000 cells per
hemisphere. After a second three-minute wait period,
the microsyringe was withdrawn at a steady rate over a
three-minute period. The same procedure was then
followed on the opposite hemisphere, the burr holes were
sealed with bone wax, and the wound was closed using
sterile wound clips (7 mm; CellPoint Scientific, Inc,
Gaithersburg, MD, USA). The mice were then placed
in a recovery cage until fully mobile, at which point,
they were returned to their homecage.
Behavioral analysis
All mice were tested for baseline behavior at five weeks
of age, prior to cell transplantation. Following a one-week
resting period after transplantation, the mice were tested
weekly for six weeks, on all behavioral tasks, except for
the Morris Water Maze (MWM), for which testing started
at two weeks post-transplantation. The rotarod task (using
the SDI Rotor-Rod; San Diego Instruments, San Diego, CA,
USA) was conducted to assess motor coordination. The
mice were required to maintain their balance on a 3-cm
diameter rotating rod for 60 seconds. The rotarod was set
at a constant speed of 10 rpm and each mouse was given
three trials per day. If the mouse was incapable of
remaining on the rotarod for the full 60 seconds, they
fell onto a foam pad placed below the apparatus.The mice also had their limb-clasping response recorded,
which involved suspending them by their tails from a
height of 50 cm for 30 seconds. A limb-clasping response
was defined as the withdrawal of any limb to the torso for
more than one second. Each testing session consisted
of three trials, with a clasping score ranging from 0 to 4
(with 0 representing the absence of clasping, 1 representing
a withdrawal of any single limb, 2 representing the with-
drawal of any two limbs, 3 representing the withdrawal of
any three limbs, and 4 representing the withdrawal of all
four limbs). The limb-clasping response scores were aver-
aged for each testing session for each animal.
The MWM was used to assess cognitive function
through spatial memory. Briefly, the MWM is a 142 cm
diameter tank filled with opaque water (30.5 cm deep
water mixed with non-toxic white paint). A platform
(14 cm diameter) was placed just below (approximately
1 cm) the surface of the water. Prior to the baseline testing
week, each mouse was given a cued trial, where the plat-
form was placed in the center of the MWM with a visible
flag attached 15 cm overhead. The mice were given four
training trials from four starting locations (North, South,
East, and West) which shaped them to swim to the escape
platform and to ensure that their visual acuity and
swimming ability were intact. During each weekly testing
period, the location of the hidden platform was altered
between the Northwest and Northeast quadrant (with
the platform in the center of these quadrants). During
baseline and the subsequent testing days, the mice were
placed facing the wall of the tank on the center line at
the tank’s Southern-most point and given sixty seconds
to find the hidden platform. Following a successful trial,
the mice were left on the platform for five seconds, re-
moved from the tank, dried, and given a forty-five second
inter-trial interval. Mice who did not locate the hidden
platform within 60 seconds were guided by hand to the
platform and allowed to rest on the platform for five
seconds. Mice were given five trials per testing session.
The swim speed, distance travelled and latency to escape
were tracked and recorded using Viewpoint VideoTrack
version 1.75. Measures recorded included latency to find
the platform, distance swum, swim speed and the prob-
ability of finding the escape platform (number of correct
trials/total trials).
Histological analysis
At the conclusion of behavioral testing, when the mice
were 11.5 weeks old, they were deeply anesthetized and
overdosed with sodium pentobarbital (delivered i.p.) and
transcardially perfused with 0.1 M PBS, followed by 4%
paraformaldehyde (diluted in 0.1 M PBS at pH 7.4) to fix
the tissue of the animal. The brains were then rapidly
removed, suspended in 4% paraformaldehyde for 24 hours
at 4°C and then transferred to 30% sucrose in 0.1 M PBS
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using methylbutane and stored at −80°C until they were
processed. Coronal sections were cut on a cryostat (Vibro-
tome UltraPro 5000; Sim Co Ltd, Denizli, Turkey) at 30 μm
and were mounted on positive charged microscope slides
(Globe Scientific Inc, Paramus, NJ, USA). The tissue was la-
beled, using previously established free-floating fluorescent
staining protocols [27] using antibodies for neuronal nuclei
(mouse NeuN; 1/500, Abcam) and glial fibrillary acidic
protein (rabbit GFAP; 1/500, Abcam). For immunohis-
tochemical analysis, the tissue was first blocked using 10%
normal goat serum in PBS with 0.1% Triton-X (Sigma) for
45 minutes at room temperature. The tissue was then
transferred to a well containing the primary antibodies
and stored at 4°C overnight. The following day, the tis-
sue was rinsed three times in PBS with 0.1% Triton-X
and transferred to a well containing the appropriately
conjugated secondary antibodies for one hour at room
temperature. Secondary antibodies (1/300; Invitrogen)
consisted of anti-rabbit AlexaFluor488 and anti-mouse
AlexaFluor594. Images of the fluorescent labels were
captured using a Zeiss Axiovert 200 M inverted fluores-
cent microscope at 20x magnification.
Cytochrome oxidase (CYO) histology was used to pro-
vide a terminal measure of metabolic activity in the tissue
and these sections were also used for subsequent morpho-
logical analyses. Briefly, tissue designated for CYO analysis
was submersed in a solution of 800 mg of sucrose (Sigma),
4 mg of cytochrome C (Sigma) and 1 mg of 3, 3'-diami-
nobenzidine (DAB, Vector Laboratories, Burlingame,
CA, USA) dissolved in 20 mL of phosphate-buffer for four
hours at room temperature. The tissue was then trans-
ferred to deionized H2O, mounted onto positively charged
glass slides and coverslipped using Depex (Electron
Microscopy, Hatfield, PA, USA). CYO labelled tissue was
scanned using Nikon ScanPro.
All images were analyzed using ImageJ (NIH; Bethesda,
MD, USA). Briefly, images of the transplanted cells
were captured from five sections of each animal, start-
ing at 0.5 mm anterior to bregma and two sections,
approximately 200 μm apart, anterior and posterior to
the transplant site. Average intensity of the label,
counts of positively labeled cells, as well as percent of
co-localization between the transplanted MSCs and
NeuN or GFAP, were analyzed in all groups. Densito-
metric measures of CYO and GFAP were analyzed
from images taken in the striatum and the average in-
tensities were normalized to the corpus callosum. Cells
were counted as positive if they showed: (1) antibody
immunoreactivity within the cell body; (2) the nucleus
of that cell was within the counting frame without
touching the exclusion lines; and (3) the nucleus of
that cell was in focus. For total brain area, five sections
(at approximately 100-, 300-, 500-, 700-, and 900 μmanterior to bregma) were traced using ImageJ and the
total area was calculated.
Statistical analysis
All statistical analyses were performed using SPSS v16
with an alpha level equal to 0.05. All behavioral data were
analyzed using a repeated measures analysis of variance
(ANOVA) to measure changes between genotypes and
treatments across weeks. Histological data were analyzed
using a multivariate ANOVA. When appropriate, Tukey’s
Honestly Significant Difference (Tukey’s HSD) post hoc
tests were performed.
Results
In vitro cell characterization
Measures of ICC for both low- and high-passage UC
MSCs showed positive expression of SCA1, a marker of
mouse MSCs (Figure 1). Flow cytometry revealed that
low-passage UC MSCs displayed 26.9% positive expression
of SCA-1 and high-passage UC MSCs displayed 30.3%
positive expression of SCA-1 (Table 2), contrasting with
what was observed previously, where expression of SCA1
increased over passages in bone-marrow derived MSCs.
Flow cytometry confirmed ICC analysis revealing that
20.5% of the low-passaged UC MSCs were positive for
CD45, a marker of hematopoietic stem cells, while 1.7% of
the high-passaged UC MSCs were positive for CD45. The
high expression of CD45 at low-passage is most likely due
to the fact that the UC MSCs are isolated from tissues
containing umbilical cord blood, which contains a high
proportion of hematopoietic stem cells. However, these
data indicate that CD45 expression is decreasing over
passages, either due to prolonged exposure to culture
conditions or a selection process occurring during the
expansion of cells. Flow cytometry data also revealed
that SSEA4, a marker of stem cells, increased from 10.9%
in low-passaged UC MSCs to 55.4% in high-passaged UC
MSCs. MHC Class I expression remained relatively stable
between low- and high-passaged UC MSCs, 2.9% and
1.8%, respectively. However, MHC Class II expression
decreased from 10.8% to 1.5% between low- and high-
passaged UC MSCs, respectively, suggesting a purification
of the MSCs over time.
Characterization of UC MSCs through mRNA isolation
and RT-PCR revealed significant differences in gene expres-
sion of BDNF between low- and high-passaged UC MSCs
(t(4) = 21.488, P <0.001), with low-passaged cells displaying
a significantly higher expression of the mRNA for BDNF
(Figure 2).
Behavioral results
In the rotarod task, a repeated-measures ANOVA revealed
significant between-group differences for the latency to
fall (F(3,36) = 13.575, P <0.01) (Figure 3). A significant
Figure 1 Immunocytochemistry (ICC) of low- and high-passaged umbilical cord mesenchymal stem cells (UC MSCs). Low- and
high-passaged UC MSCs expressed the MSC marker SCA1, were negative for the hematopoietic stem cell marker CD45 and displayed typical
MSC morphology. Scale bar represents 100 μm.
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(F(18,216) = 5.286, P <0.001). Tukey’s HSD analysis revealed
significant differences between R6/2 and WT mice starting
at six weeks of age and remaining for all testing weeks.
Transplantation of low-passage UC MSCs did not confer
significant motor benefits, as these animals were similar to
R6/2 control mice at all time points. However, significant
differences were observed between R6/2 and high-passage
UCB MSC mice at 10 weeks of age.
Given the high-degree of variability on measures of
latency to find the platform and in the distance swum,
the probability of finding the hidden platform was used
for these analyses. In the MWM task, a repeated-measures
ANOVA revealed significant differences between groups
for the probability of correctly finding the hidden platform
(F(3,37) = 4.806, P <0.01)(Figure 4). Each trial was scored
as ‘correct’ if the mouse was capable of finding the hidden
platform in less than sixty seconds and the probability
of a ‘correct’ trial was calculated at the end of each testing
session (number of correct trials/number of total trials). In
this task, untreated R6/2 mice begin to display impairmentTable 2 Flow cytometry results of low- and high-passaged
umbilical cord mesenchymal stem cells (UC MSCs)




MHC Class I 2.9 1.8
MHC Class II 10.8 1.5
The number of cells positively expressing SCA1 remained relatively stable as
passage number increased. A decrease in the hematopoietic stem cell marker
CD45 was observed as cell passage increased. Also, an increase of expression
of the stem cell marker SSEA4 between low- and high-passaged cells occurred.
Expression of MHC Class I remained relatively stable between low- and high-
passaged cells, but a decrease in MHC Class II was observed between low- and
high-passaged cells, respectively. MHC, major histological complex; SSEA4,
stage specific embryonic antigen 4.in spatial memory beginning at nine weeks of age and
continuing for the duration of the study. Significant
differences were also observed between WT and low-
passage UC MSC at seven-, eight- and ten-weeks of age.
Significant differences were also observed between WT
and high-passage UC MSC at eight-, nine- and ten-weeks
of age. Although no significant differences were observed
between the UC MSC transplant groups and the untreated
R6/2 group, an intermediate effect was observed at 11-
weeks of age, with the transplanted groups displaying
trends towards (low-passage P = 0.13; high-passage P =
0.10) having a higher probability of finding the hidden
platform than untreated R6/2 mice. It is important to
note that the R6/2 mice did not display motor deficitsFigure 2 In vitro quantitative RT-PCR of BDNF mRNA expression
of umbilical cord mesenchymal stem cells (UC MSCs). A
significant decrease in mRNA levels of BDNF was observed in the
high-passaged UC MSCs compared to low-passaged UC MSCs.
(Note: † significant from high-passage UC MSCs; TTF are control
cDNA isolated from mice tail-tip fibroblasts.) Bar graph represents mean
value; error bars represents SEM. BDNF, brain-derived neurotrophic
factor; SEM, standard error of the mean.
Figure 3 Motor coordination assessment of R6/2 mice following umbilical cord mesenchymal stem cell (UC MSC) transplantation.
A significant decline in motor coordination was observed in untreated R6/2 mice when compared to WT mice. The R6/2 mice that received
transplantation of high-passage UC MSCs displayed significantly longer latencies to fall, compared to untreated R6/2 mice at ten weeks of age.
(Note: *significant from WT; #significant from R6/2; †significant from high-passage UC MSCs). Line graph represents mean value; error bars
represents SEM. SEM, standard error of the mean; WT, wild type.
Figure 4 Spatial memory assessment of R6/2 mice following umbilical cord mesenchymal stem cell (UC MSC) transplantation. Untreated
R6/2 mice displayed significant impairment in spatial memory at 9-, 10- and 11-weeks of age when compared to WT mice. Mice receiving either
low- or high-passaged UC MSCs did not display sparing of this spatial memory task. (Note: *significant from WT) Bar graph represents mean value;
error bars represents SEM. SEM, stanrard error of the mean; WT, wild type.
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to WT mice throughout all testing periods. However,
their ability to locate the hidden platform within the
60-second trial period was significantly different than
WT mice, and this deficit was mitigated somewhat by
the UC MSC transplants.
A repeated-measures ANOVA revealed significant differ-
ences between groups for limb-clasping (F(3,42) = 8.259,
P <0.001), and a significant interaction was observed
between weeks and group (F(18,252) = 4.845, P <0.001)
(Figure 5). This phenotypic difference observed in R6/2
mice began at eight weeks of age. No effect of UC MSC
transplantation was observed, as all transplanted animals
had similar scores, relative to untreated R6/2 mice. Con-
trary to what has been previously observed in our lab using
bone-marrow MSCs, a reduction of the limb-clasping was
not observed in the animals that received transplantation
of UC MSCs.
Histological results
Following perfusion and histochemical analysis of CYO
labelled tissue, a one-way ANOVA revealed significant
between group differences in the area of the whole brain
from the sections analyzed (F(3,109) = 4.414, P <0.01)
(Figure 6A and B). Tukey’s HSD analysis revealed that
the untreated R6/2 mice had significantly smaller brain
areas than did WT mice, suggesting generalized brainFigure 5 Limb-clasping of R6/2 mice following umbilical cord mesenc
had significantly more limb-clasping responses than did WT mice, starting
of the study. Mice receiving either low- or high-passaged UC MSCs were si
from R6/2; †significant from high-passage BM MSCs). Line graph represents m
error of the mean; WT, wild type.atrophy. The mice that received transplantation of high-
passaged UC MSCs did not significantly differ from WT
mice on measures of brain area, an observation that was
not detected in the low-passaged UC MSC transplanted
mice. Optical densitometric measures of metabolic activity
of striatal tissue revealed a significant between-group dif-
ference (F(3,109) = 7.846, P <0.001) (Figure 6C). Tukey’s
HSD tests revealed that R6/2 mice had significantly less
CYO labeling than WT and R6/2 mice transplanted with
low- or high-passage UC MSCs. While transplantation of
low-passage UC MSCs did not protect against the loss of
overall brain area, the low-passaged UC MSCs were able
to reduce the loss of metabolic activity in striatal tissue,
compared to untreated R6/2 mice as determined by optical
densitometric measures. Transplantation of high-passaged
UC MSCs preserved significantly more metabolic activity
in striatal tissue than what was observed in either untreated
R6/2 mice or, interestingly, WT mice.
Student’s t-test revealed a significant difference in the
number of surviving UC MSCs between the low- and high-
passaged groups at six weeks following transplantation
(t(55) = 3.104, P <0.05) (Figure 7B). It was observed that
mice receiving transplantation of high-passage UC MSCs
had significantly more surviving cells at six weeks post-
transplantation than mice receiving low-passaged UC
MSCs. This may explain why mice receiving high-passage
UC MSCs tended to show slightly more behavioral sparing,hymal stem cell (UC MSC) transplantation. Untreated R6/2 mice
at eight-weeks of age, with this impairment continuing for the duration
milar to untreated R6/2 mice. (Note: *significant from WT; #significant
ean value; error bars represents SEM. BM, bone marrow; SEM, standard
Figure 6 Measures of brain area and evidence of integrity of the metabolic tissue in the striata of mice receiving umbilical cord
mesenchymal stem cell transplantations. Gross morphology of the brain near the area of transplantation can be visualized with cytochrome
oxidase labeling (A). Untreated R6/2 mice and mice that received transplantation of low-passaged UCMSCs had a significant decrease in total
brain area when compared to WT mice (B). Optical densitometric measures of cytochrome oxidase in the striata (outlined in dashed line) revealed
significantly less metabolic activity of striatal tissue in untreated R6/2 mice, when compared to WT mice at the time of necropsy (C). R6/2 mice
that received transplantation of low- or high-passaged UC MSCs had significantly higher levels of metabolic activity in striatal tissue than did
untreated R6/2 mice. (Note: *significant from WT; #significant from R6/2). Line graph represents mean value; error bars represent SEM. SEM,
standard error of the mean; UCMSCs, umbilical cord mesenchymal stem cells; WT, wild type.
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of metabolic activity in the striatum than mice receiving
low-passage UC MSCs, in spite of the fact that low-
passaged UC MSCs had a higher expression of BDNF
in vitro. Student’s t-test revealed no significant between-
group differences in measures of optical densitometry of
GFAP from the area around the transplant site (t(55) =
2.265, P >0.05)(Figure 7C). These data suggest that the
deficits observed in the R6/2 mice are probably not due to
astrocyte activation, and any behavioral or histological
sparing that was observed is unlikely to be due to either
the up- or down-regulation of astrocytes in the brain.
It also demonstrates that the number of passages a cell
undergoes does not significantly modulate astrocyte
activation following intra-striatal transplantation.
In contrast to what was hypothesized, little to no
co-localization of the transplanted UC MSCs with the
mature neuronal marker NeuN was revealed, suggesting
that these cells did not differentiate into mature neuronsin vivo following transplantation. This is in contrast to
what has been previously reported following transplant-
ation of UC MSCs in the brain [22-25], but similar to
what has been observed following bone-marrow MSC
transplantation [7,27,29,30].
Discussion
The four main findings of this study were: (1) transplant-
ation of UC MSCs into the striata of R6/2 mice provided
transient behavioral sparing compared to mice that did
not receive stem cell transplants; (2) transplantation of
high-passage UC MSCs resulted in a significant reduction
in neuropathology, albeit providing only transient behav-
ioral sparing; (3) the number of times the cells were
passaged significantly altered the number of surviving
cells and the astrocyte activation to the transplant 6.5 weeks
following the transplant; and 4) while the UC MSCs did
express the mRNA for BDNF in vitro, this alone was not
able to provide significant behavioral sparing, suggesting
Figure 7 Immunohistochemical analysis of the transplanted umbilical cord mesenchymal stem cells (UC MSCs). No neuronal or glial
differentiation was observed from the transplanted UC MSCs as seen by the lack of co-localization between the UC MSCs (blue) with NeuN (red)
or GFAP (green), respectively (A). A decreased significant difference in the amount of surviving transplanted cells was observed in low-passage
UC MSCs, when compared to high-passage UC MSCs (B). A significant increase in GFAP optical densitometry around the transplant site was
observed in the R6/2 mice that received transplantation of low-passage UC MSCs (C). GFAP, glial fibrillary acidic protein; NeuN, neuronal nuclei.
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transplantation of UC MSCs is not solely due to BDNF
expression but likely due to a release of several trophic
factors and immunomodulating cytokines [27].
Data from this study demonstrate that transplantation
of UC MSCs, while providing transient behavioral sparing,
did not provide robust reductions of deficits to the extent
of those previously observed in our lab following transplan-
tations of bone-marrow-derived MSCs [7,29,30]. Trans-
plantation of high-passaged UC MSCs were capable of
delaying the motor deficits compared to untreated R6/2
mice when the mice were 6- and 10-weeks of age. An
intermediate effect was observed in mice receiving UC
MSC transplants in the MWM at 11-weeks of age.
While long-term behavioral sparing was not observed
following intrastriatal UC MSC transplantation in these
mice, significant reductions in neuropathology, in terms of
preserved optical densitometric measures of CYO labeling
in the striatum of R6/2 mice that received either low- or
high-passaged UC MSCs. In addition, mice that received
high-passaged UC MSCs also did not show overall brain
atrophy when compared to untreated R6/2 mice. The
trend for reduced neuropathological deficits observed in
the high-passaged group, relative to the low-passagedgroup may, in part, be due to the number of surviving
cells, as well as a reduced immune response to those cells.
It was observed that there were significantly more surviving
cells in the high-passaged group and that there was an
increase in the optical densitometric measures of GFAP
in the low-passaged group, when compared to the high-
passaged group, suggesting that the low-passaged group
may be subjected to a greater immune response, resulting
in fewer surviving cells.
Because our results suggested that high-passaged UC
MSCs tend to provide greater behavioral and neuropatho-
logical sparing than low-passaged UC MSCs, we were
surprised that the low-passaged UC MSCs displayed a
higher expression of mRNA for BDNF in vitro. This
suggests that the mechanism underlying MSC-mediated
recovery is not solely dependent on BDNF, but probably
involves a host of other trophic and immunomodulatory
factors. Surprisingly, mRNA expression of BDNF in UC
MSCs are in contrast to what was previously observed in
our study with bone-marrow MSCs, whereby murine
MSCs that have been maintained in culture for more than
40 passages had higher expression of BDNF mRNA than
those that had been maintained in culture for less than
eight passages. While it has been suggested that deficits in
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of HD [31] and the increasing levels of BDNF may
underscore behavioral sparing following MSC transplant-
ation into rodent models of HD, the immune response to
these cells also needs to be closely examined, as has been
observed in other studies [7,8,27,29].
A main goal of utilizing MSCs isolated from the UC was
that these cells may possess greater levels of pluripotency
than other adult MSCs, due to their intermediate develop-
mental status between the fetus and the adult. However,
in our lab, MSCs isolated from the UC, while displaying
typical MSC morphology and protein expression, did not
express markers of pluripotency and were unable to differ-
entiate into neuronal phenotypes in vivo following intras-
triatal transplantation. While we were unable to discern
umbilical cord blood from Wharton’s jelly during cell
isolation, the cells isolated did display characteristics of
MSCs and were able to confer modest behavioral and
anatomical sparing.Conclusions
The results from this study demonstrate that UC MSCs
may hold significant therapeutic value for reducing the
neuropathological changes observed in the R6/2 rodent
model of HD. While the cells cultured in our standard
MSC medium did not express markers of pluripotency,
changing the protocols for cell extraction from the umbil-
ical cord [17,20] or exposing the UC MSCs to different
culture conditions [19] may increase the therapeutic effi-
cacy of these cells. Stem cells from perinatal sources are
gaining interest for clinical applications as these cells carry
fewer ethical concerns and are easily isolated after birth.
Our findings highlight the use of mesenchymal stem cells
isolated from the umbilical cord, but other sources of
extra-embryonic sources are gaining interest as well,
such as the placenta [32]. In addition, new sources of
pluripotent stem cells are being considered for transplant-
ation therapies in neurodegenerative diseases [33,34], and
extra-embryonic cells may provide a viable starting cell
to generate therapeutically relevant induced pluripotent
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